For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.
Scope of the Report:
The classification of Docetaxel includes 20 mg/ml, 40 mg/ml and 60 mg/ml. And the proportion of 20 mg/ml in 2017 is about 86% and the proportion is stable from 2013 to 2017.
Docetaxel is widely used For Breast Cancer, Prostate Cancer, Non-small Cell Lung Cancer and Cancer. The most proportion of Docetaxel used for Breast Cancer and the proportion in 2017 is 85%.
The worldwide market for Docetaxel is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Docetaxel in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Hengrui Medicine
- Sanofi
- Qilu Pharma
- Shenzhen Main Luck Pharma
- Jiangsu Aosaikang Pharma
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 20 mg/ml
- 40 mg/ml
- 60 mg/ml
Market Segment by Applications, can be divided into
- Breast Cancer
- Prostate Cancer
- Non-small Cell Lung Cancer
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Docetaxel product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Docetaxel, with price, sales, revenue and global market share of Docetaxel in 2017 and 2018.
Chapter 3, the Docetaxel competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Docetaxel breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Docetaxel market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Docetaxel sales channel, distributors, customers, research findings and conclusion, appendix and data source.